Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

This is a subject single blinded, randomized, placebo-controlled, single dose, first-time-in-human study with three or more ascending cohorts.

Phase 1

Neuralstem Inc.